Diabetes Mellitus and Anesthesia

Anesthesiology Clinics of North America

Volumn 24, Issue 3, 2006, Pages 579-597

  Tuttnauer, Aviv ^a   Levin, Phillip D ^a,b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; BUFORMIN; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; METFORMIN; METOPROLOL; MIGLITOL; MITIGLINIDE; NATEGLINIDE; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG;

ANEMIA; ANESTHESIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FLUID RETENTION; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INTESTINE ABSORPTION; LACTIC ACIDOSIS; LUNG EDEMA; METABOLIC SYNDROME X; MORBIDITY; NONHUMAN; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PERIPHERAL EDEMA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SURGICAL MORTALITY; SURGICAL RISK; TREATMENT OUTCOME;

ANESTHESIA; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; PERIOPERATIVE CARE;

EID: 33748774913     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2006.05.006     Document Type: Review

References (159)

1. World Health Organization. Diabetes. Available at: http://www.who.int/dietphysicalactivity/publications/facts/diabetes/en/print.html. Accessed May 18, 2006.
2. National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Fact Sheet. Available at: http://www.cdc.gov/diabetes/pubs/estimates05.htm#prev. Accessed May 18, 2006.
3. Centers for Disease Control and Prevention. Prevalence of diabetes and impaired fasting glucose in adults-United States, 1999-2000. MMWR Morb Mortal Wkly Rep 52 35 (2003) 833-837
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 29 Suppl 1 (2006) S43-S48
5. Anderson R.N., and Smith B.L. Deaths: leading causes for 2002. Natl Vital Stat Rep 53 17 (2005) 1-89
6. Clement S., Braithwaite S.S., Magee M.F., et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27 2 (2004) 553-591
7. McAnulty G.R., Robertshaw H.J., and Hall G.M. Anaesthetic management of patients with diabetes mellitus. Br J Anaesth 85 1 (2000) 80-90
8. Robertshaw H.J., McAnulty G.R., and Hall G.H. Strategies for managing the diabetic patient. Best Pract Res Clin Anaesthesiol 18 4 (2004) 631-643
9. Scherpereel P.A., and Tavernier B. Perioperative care of diabetic patients. Eur J Anaesthesiol 18 5 (2001) 277-294
10. WHO criteria World Health Organization: diabetes mellitus: report of a WHO Study Group (Tech. Rep. Ser. no. 727) (1985), World Health Organization, Geneva (Switzerland)
11. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 7 (1997) 1183-1197
12. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 9491 (2005) 1059-1062
13. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 9468 (2005) 1415-1428
14. Cameron A.J., Shaw J.E., and Zimmet P.Z. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33 2 (2004) 351-375 [table.]
15. Kannel W.B., and McGee D.L. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59 1 (1979) 8-13
16. Stamler J., Vaccaro O., Neaton J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 2 (1993) 434-444
17. Lee T.H., Marcantonio E.R., Mangione C.M., et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 100 10 (1999) 1043-1049
18. Boersma E., Kertai M.D., Schouten O., et al. Perioperative cardiovascular mortality in noncardiac surgery: validation of the Lee cardiac risk index. Am J Med 118 10 (2005) 1134-1141
19. Larsen S.F., Olesen K.H., Jacobsen E., et al. Prediction of cardiac risk in non-cardiac surgery. Eur Heart J 8 2 (1987) 179-185
20. Hollenberg M., Mangano D.T., Browner W.S., et al. Predictors of postoperative myocardial ischemia in patients undergoing noncardiac surgery.The Study of Perioperative Ischemia Research Group. JAMA 268 2 (1992) 205-209
21. Hamdan A.D., Saltzberg S.S., Sheahan M., et al. Lack of association of diabetes with increased postoperative mortality and cardiac morbidity: results of 6565 major vascular operations. Arch Surg 137 4 (2002) 417-421
22. Axelrod D.A., Upchurch Jr. G.R., DeMonner S., et al. Perioperative cardiovascular risk stratification of patients with diabetes who undergo elective major vascular surgery. J Vasc Surg 35 5 (2002) 894-901
23. Boersma E., Poldermans D., Bax J.J., et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 285 14 (2001) 1865-1873
24. Subramaniam B., Pomposelli F., Talmor D., et al. Perioperative and long-term morbidity and mortality after above-knee and below-knee amputations in diabetics and nondiabetics. [table]. Anesth Analg 100 5 (2005) 1241-1247
25. Eagle K.A., Berger P.B., Calkins H., et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 105 10 (2002) 1257-1267
26. Monahan T.S., Shrikhande G.V., Pomposelli F.B., et al. Preoperative cardiac evaluation does not improve or predict perioperative or late survival in asymptomatic diabetic patients undergoing elective infrainguinal arterial reconstruction. J Vasc Surg 41 1 (2005) 38-45
27. Falcone R.A., Nass C., Jermyn R., et al. The value of preoperative pharmacologic stress testing before vascular surgery using ACC/AHA guidelines: a prospective, randomized trial. J Cardiothorac Vasc Anesth 17 6 (2003) 694-698
28. Mangano D.T., Layug E.L., Wallace A., et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 335 23 (1996) 1713-1720
29. Poldermans D., Boersma E., Bax J.J., et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 341 24 (1999) 1789-1794
30. Urban M.K., Markowitz S.M., Gordon M.A., et al. Postoperative prophylactic administration of beta-adrenergic blockers in patients at risk for myocardial ischemia. Anesth Analg 90 6 (2000) 1257-1261
31. Raby K.E., Brull S.J., Timimi F., et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. Anesth Analg 88 3 (1999) 477-482
32. Juul A.B., Wetterslev J., Kofoed-Enevoldsen A., et al. The Diabetic Postoperative Mortality and Morbidity (DIPOM) trial: rationale and design of a multicenter, randomized, placebo-controlled, clinical trial of metoprolol for patients with diabetes mellitus who are undergoing major noncardiac surgery. Am Heart J 147 4 (2004) 677-683
33. Juul AB. Randomized, blinded trial on perioperative metoprolol versus placebo for diabetic patients undergoing noncardiac surgery. Presented at Late-Breaking Clinical Trials I, American Heart Association Scientific Sessions 2004. New Orleans, Louisiana, November 7-10, 2004.
34. O'Neil-Callahan K., Katsimaglis G., Tepper M.R., et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 45 3 (2005) 336-342
35. Cheng A.Y., and Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 172 2 (2005) 213-226
36. Sheehan M.T. Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res 1 3 (2003) 189-200
37. Zimmerman B.R. Sulfonylureas. Endocrinol Metab Clin North Am 26 3 (1997) 511-522
38. Shorr R.I., Ray W.A., Daugherty J.R., et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 44 7 (1996) 751-755
39. van Staa T., Abenhaim L., and Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50 6 (1997) 735-741
40. Harrower A.D. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 31 2 (1996) 111-119
41. Gross G.J. ATP-sensitive potassium channels and myocardial preconditioning. Basic Res Cardiol 90 2 (1995) 85-88
42. Raphael J., Drenger B., Rivo J., et al. Ischemic preconditioning decreases the reperfusion-related formation of hydroxyl radicals in a rabbit model of regional myocardial ischemia and reperfusion: the role of K(ATP) channels. Free Radic Res 39 7 (2005) 747-754
43. Riveline J.P., Danchin N., Ledru F., et al. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 29 3 (2003) 207-222
44. Loubani M., Fowler A., Standen N.B., et al. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 515 1-3 (2005) 142-149
45. Meier J.J., Gallwitz B., Schmidt W.E., et al. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart 90 1 (2004) 9-12
46. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 837-853
47. Hu S., Wang S., Fanelli B., et al. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 293 2 (2000) 444-452
48. Vinambres C., Villanueva-Penacarrillo M.L., Valverde I., et al. Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets. Pharmacol Res 34 1-2 (1996) 83-85
49. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 41 7 (2002) 471-483
50. McLeod J.F. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 43 2 (2004) 97-120
51. Moses R.G., Gomis R., Frandsen K.B., et al. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 24 1 (2001) 11-15
52. Nattrass M., and Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of type 2 diabetes?. Int J Obes Relat Metab Disord 24 Suppl 3 (2000) S21-S31
53. Kirpichnikov D., McFarlane S.I., and Sowers J.R. Metformin: an update. Ann Intern Med 137 1 (2002) 25-33
54. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 8 (2001) 1167-1174
55. Inzucchi S.E., Maggs D.G., Spollett G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in Type II diabetes mellitus. N Engl J Med 338 13 (1998) 867-872
56. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 854-865
57. Lalau J.D., and Race J.M. Lactic acidosis in metformin therapy. Drugs 58 Suppl 1 (1999) 55-60
58. Bailey C.J., and Turner R.C. Metformin. N Engl J Med 334 9 (1996) 574-579
59. Lucis O.J. The status of metformin in Canada. Can Med Assoc J 128 1 (1983) 24-26
60. Salpeter S., Greyber E., Pasternak G., et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2 (2003) CD002967
61. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 11 (2004) 1106-1118
62. Aldhahi W., and Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 3 4 (2003) 293-298
63. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134 1 (2001) 61-71
64. Ghazzi M.N., Perez J.E., Antonucci T.K., et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46 3 (1997) 433-439
65. Ogihara T., Rakugi H., Ikegami H., et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8 3 (1995) 316-320
66. Kawasaki J., Hirano K., Nishimura J., et al. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation 98 22 (1998) 2446-2452
67. Marx N., Duez H., Fruchart J.C., et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 9 (2004) 1168-1178
68. Marx N., Wohrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112 18 (2005) 2792-2798
69. Choi D., Kim S.K., Choi S.H., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 11 (2004) 2654-2660
70. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 23 (2003) 2941-2948
71. In: Sweetman S.S. (Ed). Martindale. The complete drug reference. 33rd edition (2000), Pharmaceutical Press, London 334
72. Belcher G., Lambert C., Edwards G., et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract 70 1 (2005) 53-62
73. Lebovitz H.E. alpha-Glucosidase inhibitors. Endocrinol Metab Clin North Am 26 3 (1997) 539-551
74. Lebovitz H.E. Oral antidiabetic agents: 2004. Med Clin North Am 88 4 (2004) 847-863
75. Rowe R., Cowx M., Poole C., et al. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin 21 11 (2005) 1885-1890
76. Nelson R.H., and Miles J.M. The use of orlistat in the treatment of obesity, dyslipidaemia and type 2 diabetes. Expert Opin Pharmacother 6 14 (2005) 2483-2491
77. Edwards C.M. The GLP-1 system as a therapeutic target. Ann Med 37 5 (2005) 314-322
78. U.S. Food and Drug Administration. Available at: http://www.fda.gov/cder/rdmt/InternetNME05.htm. Accessed July 1, 2006.
79. Gallwitz B. Glucagon-like Peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 4 6 (2005) 361-370
80. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 289 17 (2003) 2254-2264
81. Hirsch I.B. Insulin analogues. N Engl J Med 352 2 (2005) 174-183
82. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 14 (1993) 977-986
83. Plank J., Siebenhofer A., Berghold A., et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 165 12 (2005) 1337-1344
84. Ahmed Z., Lockhart C.H., Weiner M., et al. Advances in diabetic management: implications for anesthesia. Anesth Analg 100 3 (2005) 666-669
85. Radermecker R.P., and Scheen A.J. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 20 3 (2004) 178-188
86. Cook C.B., Boyle M.E., Cisar N.S., et al. Use of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital setting: proposed guidelines and outcome measures. Diabetes Educ 31 6 (2005) 849-857
87. Nunnally M.E. Con: tight perioperative glycemic control: poorly supported and risky. J Cardiothorac Vasc Anesth 19 5 (2005) 689-690
88. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 19 (2001) 1359-1367
89. Weissman C. The metabolic response to stress: an overview and update. Anesthesiology 73 2 (1990) 308-327
90. Brierre S., Kumari R., and Deboisblanc B.P. The endocrine system during sepsis. Am J Med Sci 328 4 (2004) 238-247
91. McCowen K.C., Malhotra A., and Bistrian B.R. Stress-induced hyperglycemia. Crit Care Clin 17 1 (2001) 107-124
92. Marik P.E., and Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 30 5 (2004) 748-756
93. Werb M.R., Zinman B., Teasdale S.J., et al. Hormonal and metabolic responses during coronary artery bypass surgery: role of infused glucose. J Clin Endocrinol Metab 69 5 (1989) 1010-1018
94. Baum D., and Porte Jr. D. Stress hyperglycemia and the adrenergic regulation of pancreatic hormones in hypoxia. Metabolism 29 Suppl 1 (1980) 1176-1185
95. Bagdade J.D., Stewart M., and Walters E. Impaired granulocyte adherence. A reversible defect in host defense in patients with poorly controlled diabetes. Diabetes 27 6 (1978) 677-681
96. Kjersem H., Hilsted J., Madsbad S., et al. Polymorphonuclear leucocyte dysfunction during short term metabolic changes from normo- to hyperglycemia in type 1 (insulin dependent) diabetic patients. Infection 16 4 (1988) 215-221
97. Mazade M.A., and Edwards M.S. Impairment of Type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab 73 3 (2001) 259-267
98. McMahon M.M., and Bistrian B.R. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am 9 1 (1995) 1-9
99. Mowat A., and Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 284 12 (1971) 621-627
100. Oldenborg P.A., and Sehlin J. Effects of D-glucose on chemokinesis and resting production of reactive oxygen species in neutrophil granulocytes of lean or obese-hyperglycemic mouse. Biosci Rep 17 5 (1997) 487-498
101. Oldenborg P.A., and Sehlin J. Hyperglycemia in vitro attenuates insulin-stimulated chemokinesis in normal human neutrophils. Role of protein kinase C activation. J Leukoc Biol 65 5 (1999) 635-640
102. Marhoffer W., Stein M., Maeser E., et al. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 15 2 (1992) 256-260
103. Nolan C.M., Beaty H.N., and Bagdade J.D. Further characterization of the impaired bactericidal function of granulocytes in patients with poorly controlled diabetes. Diabetes 27 9 (1978) 889-894
104. Hostetter M.K. Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 39 3 (1990) 271-275
105. Mohanty P., Hamouda W., Garg R., et al. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85 8 (2000) 2970-2973
106. Dhindsa S., Tripathy D., Mohanty P., et al. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism 53 3 (2004) 330-334
107. Straczkowski M., Dzienis-Straczkowska S., Stepien A., et al. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 87 10 (2002) 4602-4606
108. Giugliano D., Marfella R., Coppola L., et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95 7 (1997) 1783-1790
109. Dandona P., Mohanty P., Chaudhuri A., et al. Insulin infusion in acute illness. J Clin Invest 115 8 (2005) 2069-2072
110. Dandona P., Aljada A., Mohanty P., et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?. J Clin Endocrinol Metab 86 7 (2001) 3257-3265
111. Aljada A., Ghanim H., Mohanty P., et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 87 3 (2002) 1419-1422
112. Pomposelli J.J., Baxter III J.K., Babineau T.J., et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr 22 2 (1998) 77-81
113. Bochicchio G.V., Salzano L., Joshi M., et al. Admission preoperative glucose is predictive of morbidity and mortality in trauma patients who require immediate operative intervention. Am Surg 71 2 (2005) 171-174
114. Furnary A.P., Wu Y., and Bookin S.O. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. Endocr Pract 10 Suppl 2 (2004) 21-33
115. Gandhi G.Y., Nuttall G.A., Abel M.D., et al. Intraoperative hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clin Proc 80 7 (2005) 862-866
116. Golden S.H., Peart-Vigilance C., Kao W.H., et al. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 22 9 (1999) 1408-1414
117. Gore D.C., Chinkes D., Heggers J., et al. Association of hyperglycemia with increased mortality after severe burn injury. J Trauma 51 3 (2001) 540-544
118. Grey N.J., and Perdrizet G.A. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. Endocr Pract 10 Suppl 2 (2004) 46-52
119. Guvener M., Pasaoglu I., Demircin M., et al. Perioperative hyperglycemia is a strong correlate of postoperative infection in Type II diabetic patients after coronary artery bypass grafting. Endocr J 49 5 (2002) 531-537
120. Latham R., Lancaster A.D., Covington J.F., et al. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 22 10 (2001) 607-612
121. Vriesendorp T.M., Morelis Q.J., Devries J.H., et al. Early post-operative glucose levels are an independent risk factor for infection after peripheral vascular surgery. A retrospective study. Eur J Vasc Endovasc Surg 28 5 (2004) 520-525
122. Hansen T.K., Thiel S., Wouters P.J., et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88 3 (2003) 1082-1088
123. Langouche L., Vanhorebeek I., Vlasselaers D., et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 115 8 (2005) 2277-2286
124. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?. J Clin Invest 114 9 (2004) 1187-1195
125. Visser L., Zuurbier C.J., Hoek F.J., et al. Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normoglycaemic clamp: effects on inflammatory response during coronary artery surgery. Br J Anaesth 95 4 (2005) 448-457
126. Finney S.J., Zekveld C., Elia A., et al. Glucose control and mortality in critically ill patients. JAMA 290 15 (2003) 2041-2047
127. Van den Berghe G., Wouters P.J., Bouillon R., et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31 2 (2003) 359-366
128. Ouattara A., Lecomte P., Le Manach Y., et al. Poor intraoperative blood glucose control is associated with a worsened hospital oOutcome after cardiac surgery in diabetic patients. Anesthesiology 103 4 (2005) 687-694
129. Zerr K.J., Furnary A.P., Grunkemeier G.L., et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 63 2 (1997) 356-361
130. Doenst T., Wijeysundera D., Karkouti K., et al. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 130 4 (2005) 1144-1150
131. Lazar H.L., Chipkin S.R., Fitzgerald C.A., et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 109 12 (2004) 1497-1502
132. Zygun D.A., Steiner L.A., Johnston A.J., et al. Hyperglycemia and brain tissue pH after traumatic brain injury. Neurosurgery 55 4 (2004) 877-882
133. Lam A.M., Winn H.R., Cullen B.F., et al. Hyperglycemia and neurological outcome in patients with head injury. J Neurosurg 75 4 (1991) 545-551
134. Margulies D.R., Hiatt J.R., Vinson Jr. D., et al. Relationship of hyperglycemia and severity of illness to neurologic outcome in head injury patients. Am Surg 60 6 (1994) 387-390
135. Rovlias A., and Kotsou S. The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery 46 2 (2000) 335-342
136. Young B., Ott L., Dempsey R., et al. Relationship between admission hyperglycemia and neurologic outcome of severely brain-injured patients. Ann Surg 210 4 (1989) 466-472
137. Yang S.Y., Zhang S., and Wang M.L. Clinical significance of admission hyperglycemia and factors related to it in patients with acute severe head injury. Surg Neurol 44 4 (1995) 373-377
138. Van den Berghe G., Schoonheydt K., Becx P., et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 64 8 (2005) 1348-1353
139. Laird A.M., Miller P.R., Kilgo P.D., et al. Relationship of early hyperglycemia to mortality in trauma patients. J Trauma 56 5 (2004) 1058-1062
140. Yendamuri S., Fulda G.J., and Tinkoff G.H. Admission hyperglycemia as a prognostic indicator in trauma. J Trauma 55 1 (2003) 33-38
141. Malmberg K., Ryden L., Efendic S., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26 1 (1995) 57-65
142. Capes S.E., Hunt D., Malmberg K., et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355 9206 (2000) 773-778
143. Fath-Ordoubadi F., and Beatt K.J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96 4 (1997) 1152-1156
144. Capes S.E., Hunt D., Malmberg K., et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32 10 (2001) 2426-2432
145. O'Neill P.A., Davies I., Fullerton K.J., et al. Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 22 7 (1991) 842-847
146. Kagansky N., Levy S., and Knobler H. The role of hyperglycemia in acute stroke. Arch Neurol 58 8 (2001) 1209-1212
147. Juvela S., Siironen J., and Kuhmonen J. Hyperglycemia, excess weight, and history of hypertension as risk factors for poor outcome and cerebral infarction after aneurysmal subarachnoid hemorrhage. J Neurosurg 102 6 (2005) 998-1003
148. Krinsley J.S. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 78 12 (2003) 1471-1478
149. Krinsley J.S. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79 8 (2004) 992-1000
150. Schricker T., Lattermann R., Wykes L., et al. Effect of i.v. dextrose administration on glucose metabolism during surgery. JPEN J Parenter Enteral Nutr 28 3 (2004) 149-153
151. Schricker T., Lattermann R., and Carli F. Intraoperative protein sparing with glucose. J Appl Physiol 99 3 (2005) 898-901
152. Lattermann R., Carli F., Wykes L., et al. Perioperative glucose infusion and the catabolic response to surgery: the effect of epidural block. [table]. Anesth Analg 96 2 (2003) 555-562
153. Geisser W., Schreiber M., Hofbauer H., et al. Sevoflurane versus isoflurane-anaesthesia for lower abdominal surgery. Effects on perioperative glucose metabolism. Acta Anaesthesiol Scand 47 2 (2003) 174-179
154. Lattermann R., Schricker T., Wachter U., et al. Laparoscopic-assisted vaginal hysterectomy and the hyperglycemic response to surgery: an observational study. Can J Anaesth 48 9 (2001) 871-875
155. Sieber F., Smith D.S., Kupferberg J., et al. Effects of intraoperative glucose on protein catabolism and plasma glucose levels in patients with supratentorial tumors. Anesthesiology 64 4 (1986) 453-459
156. Lattermann R., Belohlavek G., Wittmann S., et al. The anticatabolic effect of neuraxial blockade after hip surgery. [table]. Anesth Analg 101 4 (2005) 1202-1208
157. Barker J.P., Robinson P.N., Vafidis G.C., et al. Metabolic control of non-insulin-dependent diabetic patients undergoing cataract surgery: comparison of local and general anaesthesia. Br J Anaesth 74 5 (1995) 500-505
158. Glaser F., Sannwald G.A., Buhr H.J., et al. General stress response to conventional and laparoscopic cholecystectomy. Ann Surg 221 4 (1995) 372-380
159. Schricker T., Gougeon R., Eberhart L., et al. Type 2 diabetes mellitus and the catabolic response to surgery. Anesthesiology 102 2 (2005) 320-326